These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 32562573)
1. Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly Population. Lewis JP; Riaz M; Xie S; Polekhina G; Wolfe R; Nelson M; Tonkin AM; Reid CM; Murray AM; McNeil JJ; Shuldiner AR; Lacaze P Clin Pharmacol Ther; 2020 Dec; 108(6):1289-1298. PubMed ID: 32562573 [TBL] [Abstract][Full Text] [Related]
2. Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. Xu K; Ye S; Zhang S; Yang M; Zhu T; Kong D; Chen J; Xu L; Li J; Zhu H; Wang F; Yang L; Zhang J; Fan Y; Ying L; Hu X; Zhang X; Chan NC; Li C Circ Cardiovasc Interv; 2019 May; 12(5):e007019. PubMed ID: 31018667 [TBL] [Abstract][Full Text] [Related]
3. Prospective Evaluation of Genetic Variation in Platelet Endothelial Aggregation Receptor 1 Reveals Aspirin-Dependent Effects on Platelet Aggregation Pathways. Backman JD; Yerges-Armstrong LM; Horenstein RB; Newcomer S; Shaub S; Morrisey M; Donnelly P; Drolet M; Tanner K; Pavlovich MA; O'Connell JR; Mitchell BD; Lewis JP Clin Transl Sci; 2017 Mar; 10(2):102-109. PubMed ID: 28075528 [TBL] [Abstract][Full Text] [Related]
4. The PAR4 Platelet Thrombin Receptor Variant rs773902 does not Impact the Incidence of Thrombotic or Bleeding Events in a Healthy Older Population. Selvadurai MV; Riaz M; Xie S; Tonkin AM; McNeil JJ; Lacaze P; Hamilton JR Thromb Haemost; 2022 Jul; 122(7):1130-1138. PubMed ID: 34852379 [TBL] [Abstract][Full Text] [Related]
5. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. McNeil JJ; Wolfe R; Woods RL; Tonkin AM; Donnan GA; Nelson MR; Reid CM; Lockery JE; Kirpach B; Storey E; Shah RC; Williamson JD; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Orchard SG; Trevaks RE; Beilin LJ; Johnston CI; Ryan J; Radziszewska B; Jelinek M; Malik M; Eaton CB; Brauer D; Cloud G; Wood EM; Mahady SE; Satterfield S; Grimm R; Murray AM; N Engl J Med; 2018 Oct; 379(16):1509-1518. PubMed ID: 30221597 [TBL] [Abstract][Full Text] [Related]
6. Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Lewis JP; Ryan K; O'Connell JR; Horenstein RB; Damcott CM; Gibson Q; Pollin TI; Mitchell BD; Beitelshees AL; Pakzy R; Tanner K; Parsa A; Tantry US; Bliden KP; Post WS; Faraday N; Herzog W; Gong Y; Pepine CJ; Johnson JA; Gurbel PA; Shuldiner AR Circ Cardiovasc Genet; 2013 Apr; 6(2):184-92. PubMed ID: 23392654 [TBL] [Abstract][Full Text] [Related]
7. Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Peng LL; Zhao YQ; Zhou ZY; Jin J; Zhao M; Chen XM; Chen LY; Cai YF; Li JL; Huang M Acta Pharmacol Sin; 2016 Nov; 37(11):1442-1448. PubMed ID: 27641736 [TBL] [Abstract][Full Text] [Related]
8. Effect of PEAR1, PTGS1 gene polymorphisms on the recurrence of aspirin-treated patients with ischemic stroke in the Han population of China: A 4-year follow-up study. Zhang L; Meng Z; Wang H; Miao Y Medicine (Baltimore); 2024 May; 103(19):e38031. PubMed ID: 38728491 [TBL] [Abstract][Full Text] [Related]
9. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Steinhubl SR; Bhatt DL; Brennan DM; Montalescot G; Hankey GJ; Eikelboom JW; Berger PB; Topol EJ; Ann Intern Med; 2009 Mar; 150(6):379-86. PubMed ID: 19293071 [TBL] [Abstract][Full Text] [Related]
10. Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Long-Term Cerebrovascular Outcomes in Patients With Minor Stroke or Transient Ischemic Attack. Zhang XG; Gu JY; Fu QQ; Chen SW; Xue J; Jiang SS; Kong YM; Li YM; Yue YH Front Neurol; 2021; 12():649056. PubMed ID: 34135847 [No Abstract] [Full Text] [Related]
11. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114 [TBL] [Abstract][Full Text] [Related]
12. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. ; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931 [TBL] [Abstract][Full Text] [Related]
13. Targeted deep sequencing of the PEAR1 locus for platelet aggregation in European and African American families. Keramati AR; Yanek LR; Iyer K; Taub MA; Ruczinski I; Becker DM; Becker LC; Faraday N; Mathias RA Platelets; 2019; 30(3):380-386. PubMed ID: 29553866 [TBL] [Abstract][Full Text] [Related]
14. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. Bhatt DL; Fox KA; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Flather MD; Haffner SM; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Brennan DM; Fabry-Ribaudo L; Booth J; Topol EJ; N Engl J Med; 2006 Apr; 354(16):1706-17. PubMed ID: 16531616 [TBL] [Abstract][Full Text] [Related]
15. Harms and Benefits of Using Aspirin for Primary Prevention of Cardiovascular Disease: A Narrative Overview. Lippi G; Danese E; Favaloro EJ Semin Thromb Hemost; 2019 Mar; 45(2):157-163. PubMed ID: 30347414 [TBL] [Abstract][Full Text] [Related]
16. Update on aspirin in the treatment and prevention of cardiovascular disease. Hennekens CH Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736 [TBL] [Abstract][Full Text] [Related]
17. Effect of Aspirin on Disability-free Survival in the Healthy Elderly. McNeil JJ; Woods RL; Nelson MR; Reid CM; Kirpach B; Wolfe R; Storey E; Shah RC; Lockery JE; Tonkin AM; Newman AB; Williamson JD; Margolis KL; Ernst ME; Abhayaratna WP; Stocks N; Fitzgerald SM; Orchard SG; Trevaks RE; Beilin LJ; Donnan GA; Gibbs P; Johnston CI; Ryan J; Radziszewska B; Grimm R; Murray AM; N Engl J Med; 2018 Oct; 379(16):1499-1508. PubMed ID: 30221596 [TBL] [Abstract][Full Text] [Related]
18. Short- and long-term impact of aspirin cessation in older adults: a target trial emulation. Zhou Z; Webb KL; Nelson MR; Woods RL; Ernst ME; Murray AM; Chan AT; Tonkin A; Reid CM; Orchard SG; Kirpach B; Shah RC; Stocks N; Broder JC; Wolfe R BMC Med; 2024 Jul; 22(1):306. PubMed ID: 39075484 [TBL] [Abstract][Full Text] [Related]
19. Impact of platelet reactivity on long-term clinical outcomes and bleeding events in Japanese patients receiving antiplatelet therapy with aspirin. Yamane K; Ikeda T; Taniguchi R; Watanabe S; Kawato M; Kondo H; Shirakawa R; Higashi T; Toma M; Tabuchi A; Tamura T; Takahashi K; Watanabe H; Yoshikawa Y; Kita T; Kimura T; Horiuchi H J Atheroscler Thromb; 2012; 19(12):1142-53. PubMed ID: 22878699 [TBL] [Abstract][Full Text] [Related]
20. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Nelson M; Reid C; Beilin L; Donnan G; Johnston C; Krum H; Storey E; Tonkin A; McNeil J; Drugs Aging; 2003; 20(12):897-903. PubMed ID: 14565783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]